Current directions for COX-2 inhibition in breast cancer

被引：29

作者：

Chow, LWC ^{[1
]}

Loo, WTY

Toi, M

机构：

[1] Univ Hong Kong, Med Ctr, Dept Hung Chao Hong, Integrated Ctr Breast Dis, Hong Kong, Hong Kong, Peoples R China

[2] Komagome Hosp, Dept Clin Trials & Res, Dept Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2005年 / 59卷

关键词：

current directions; COX-2; inhibition; breast cancer;

D O I：

10.1016/S0753-3322(05)80046-0

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Chemotherapy is effective against breast cancer. COX-2 has been implicated in the progression and angiogenesis of cancers. Celecoxib, a cyclooxygenase type 2 (COX-2) inhibitor, has both apoptotic and antiangiogenic activities, and may be of use in treatment of breast tumors which overexpress the COX-2 enzyme. Preliminary clinical trials have shown that the combination of chemotherapy with celecoxib has minimal additional toxicity and it may enhance the effects of the chemotherapy. Beside chemotherapy, celecoxib may promulgate the effect of aromatase inhibitor in breast cancer cells. Animal studies have shown that there are fewer and smaller tumors treated by combining exemestane and celecoxib. Larger clinical trials should be initiated to study the potential anti-cancer effects of celecoxib in breast cancer. (c) 2005 Elsevier SAS. All rights reserved.

引用

页码：S281 / S284

页数：4

共 50 条

[21] COX-2 dependent regulation of mechanotransduction in human breast cancer cells [J].

Yoon, A-Rum ;

Stasinopoulos, Ioannis ;

Kim, Jae Hun ;

Yong, Hwan Mee ;

Kilic, Onur ;

Wirtz, Denis ;

Bhujwalla, Zaver M. ;

An, Steven S. .

CANCER BIOLOGY & THERAPY, 2015, 16 (03) :430-437

[22] The role of COX-2 selective inhibitors in the treatment of patients with breast cancer [J].

Kolyadina, I. V. ;

Poddubnaya, I. V. ;

Komov, D. V. ;

Rostchin, E. M. ;

Ozhereliev, A. S. ;

Orinovsky, M. B. .

SOVREMENNYE TEHNOLOGII V MEDICINE, 2011, (01) :108-111

[23] Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions [J].

Pacelli, A. ;

Greenman, J. ;

Cawthorne, C. ;

Smith, G. .

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2014, 57 (04) :317-322

[24] Cox-2 expression on tissue microarray of breast cancer [J].

Park, K. ;

Han, S. ;

Shin, E. ;

Kim, H. -J. ;

Kim, J. -Y. .

EJSO, 2006, 32 (10) :1093-1096

[25] Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis [J].

Ke-Da Yu ;

Ao-Xiang Chen ;

Chen Yang ;

Li-Xin Qiu ;

Lei Fan ;

Wen-Huan Xu ;

Zhi-Ming Shao .

Breast Cancer Research and Treatment, 2010, 122 :251-257

[26] Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis [J].

Yu, Ke-Da ;

Chen, Ao-Xiang ;

Yang, Chen ;

Qiu, Li-Xin ;

Fan, Lei ;

Xu, Wen-Huan ;

Shao, Zhi-Ming .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) :251-257

[27] Cox-2 Expression in Malignant Breast Tumors [J].

An, Min-Sung ;

Kim, Sang-Hyo ;

Yoon, Hye-Kyoung ;

Kim, Woon-Won .

JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2009, 77 (06) :371-377

[28] COX-2 inhibition: A possible role in the management of prostate cancer? [J].

Sooriakumaran, P. ;

Langley, S. E. M. ;

Laing, R. W. ;

Coley, H. M. .

JOURNAL OF CHEMOTHERAPY, 2007, 19 (01) :21-32

[29] COX-2 expression in invasive breast cancer - Correlation with prognostic parameters and outcome [J].

Nassar, Aziza ;

Radhakrishnan, Anu ;

Cabrero, Isabel A. ;

Cotsonis, George ;

Cohen, Cynthia .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03) :255-259

[30] Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines [J].

Singh, Balraj ;

Irving, LaTashia R. ;

Tai, Karen ;

Lucci, Anthony .

JOURNAL OF SURGICAL RESEARCH, 2010, 163 (02) :235-243

← 1 2 3 4 5 →